ATE196847T1 - Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen - Google Patents

Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen

Info

Publication number
ATE196847T1
ATE196847T1 AT93906680T AT93906680T ATE196847T1 AT E196847 T1 ATE196847 T1 AT E196847T1 AT 93906680 T AT93906680 T AT 93906680T AT 93906680 T AT93906680 T AT 93906680T AT E196847 T1 ATE196847 T1 AT E196847T1
Authority
AT
Austria
Prior art keywords
pct
mannose
fibrotic disorders
phosphates
sec
Prior art date
Application number
AT93906680T
Other languages
English (en)
Inventor
Mark William James Ferguson
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Application granted granted Critical
Publication of ATE196847T1 publication Critical patent/ATE196847T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT93906680T 1992-03-17 1993-03-16 Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen ATE196847T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929205800A GB9205800D0 (en) 1992-03-17 1992-03-17 Treatment of fibrotic disorders
PCT/GB1993/000541 WO1993018777A1 (en) 1992-03-17 1993-03-16 Use of mannose phosphates for the treatment of fibrotic disorders

Publications (1)

Publication Number Publication Date
ATE196847T1 true ATE196847T1 (de) 2000-10-15

Family

ID=10712310

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93906680T ATE196847T1 (de) 1992-03-17 1993-03-16 Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen

Country Status (18)

Country Link
US (1) US5520926A (de)
EP (1) EP0728006B1 (de)
JP (1) JP3930556B2 (de)
AT (1) ATE196847T1 (de)
AU (1) AU667887B2 (de)
CA (1) CA2130805C (de)
DE (1) DE69329559T2 (de)
DK (1) DK0728006T3 (de)
ES (1) ES2151903T3 (de)
GB (2) GB9205800D0 (de)
GR (1) GR3035117T3 (de)
IL (1) IL105079A (de)
NO (1) NO306808B1 (de)
NZ (1) NZ249915A (de)
PT (1) PT728006E (de)
SG (1) SG49899A1 (de)
WO (1) WO1993018777A1 (de)
ZA (1) ZA931869B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
SE9403137D0 (sv) * 1994-09-20 1994-09-20 Perstorp Ab Derivatives of carbohydrates and compositions containing them
US6566339B1 (en) 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB9516012D0 (en) * 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
GB9616896D0 (en) * 1996-08-12 1996-09-25 British Tech Group Pharmaceutical compositions
US6093388A (en) * 1996-08-12 2000-07-25 Btg International Limited Mannose-6-phosphate composition and its use in treating fibrotic disorders
DE19758059C2 (de) * 1997-12-29 2001-10-04 Thorsten Marquardt Verwendung von Mannose zur Bekämpfung der Proteinverlust-Enteropathie
WO2002030432A1 (en) * 2000-06-23 2002-04-18 Cambridgemed, Inc Agent for reduction of scar formation by using wound alkalinization
DE60142632D1 (de) * 2000-11-30 2010-09-02 Novodermix Internat Ltd Heilung von wunden
US20030031689A1 (en) * 2001-08-09 2003-02-13 Thomas Mammone Method of skin exfoliation
US6822033B2 (en) 2001-11-19 2004-11-23 United States Gypsum Company Compositions and methods for treating set gypsum
JP4564261B2 (ja) * 2002-01-22 2010-10-20 ジェンザイム、コーポレーション 慢性的移植片拒絶反応の治療と予防のためのＴＧＦ−β拮抗薬の使用
EP1507543A4 (de) * 2002-05-09 2006-07-26 Cambridgemed Inc Pharmazeutische zusammensetzung zur behandlung von wunden mit blutplasma oder serum
GB0217136D0 (en) 2002-07-24 2002-09-04 Renovo Ltd Wound healing & treatment of fibrosis
KR100492913B1 (ko) * 2002-08-23 2005-06-03 주식회사 태평양 피부 감작 및 자극을 완화하는 피부 외용제 조성물
US20050136126A1 (en) * 2003-03-17 2005-06-23 Cambridgemed, Inc. Agent for reduction of scar formation by using wound alkalinization
JP4634027B2 (ja) * 2003-05-16 2011-02-16 花王株式会社 ビタミンｄ様活性代替用剤
US7276486B2 (en) * 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
WO2006044433A2 (en) * 2004-10-13 2006-04-27 The Ohio State University Research Foundation Methods to treat or prevent viral-associated lymphoproliferative disorders
US20070048391A1 (en) * 2005-08-23 2007-03-01 Cambridgemed, Inc. Composition for reduction of scar formation on wound scar
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
EP1948675B1 (de) 2005-10-25 2014-07-30 The Johns Hopkins University Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen
EP2230252A1 (de) 2006-03-13 2010-09-22 The Johns Hopkins University Erhöhung der endothelialen Thromboresistenz
EP3254696A1 (de) 2006-10-03 2017-12-13 Genzyme Corporation Verwendung von tgf-beta-antagonisten zur behandlung von kleinkindern mit dem risiko des ausbruchs von bronchopulmonaler dysplasie
US8070895B2 (en) 2007-02-12 2011-12-06 United States Gypsum Company Water resistant cementitious article and method for preparing same
US8329308B2 (en) 2009-03-31 2012-12-11 United States Gypsum Company Cementitious article and method for preparing the same
GB0910078D0 (en) 2009-06-11 2009-07-22 Renovo Ltd Uses of mannose-6-phosphate
GB0916333D0 (en) 2009-09-17 2009-10-28 Renovo Ltd Improvement of tendon repair
GB0916334D0 (en) * 2009-09-17 2009-10-28 Renovo Ltd Inhibition of tendon adhesions
HUE027831T2 (en) 2010-03-12 2016-11-28 Genzyme Corp Combination therapy for breast cancer
US20140170236A1 (en) * 2010-11-05 2014-06-19 Priscilla Hayes Petty Use of phosphoric acid
CA2823154A1 (en) 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
MX2014004994A (es) 2011-10-26 2014-08-27 Seattle Children S Res Inst Cisteamina en el tratamiento de enfermedad fibrotica.
EP2799537B1 (de) 2011-12-28 2021-09-22 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
EP3064222B1 (de) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutikum enthaltend einen tgf-beta signalblocker für erkrankungen im zusammenhang mit endoplasmatischem retikulumszelltod im hornhautendothel
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2023172636A1 (en) * 2022-03-08 2023-09-14 University Of Mississippi Medical Center Articles and methods for improved tissue healing
CN115260256A (zh) * 2022-07-22 2022-11-01 河南中医药大学 一种甘露糖磷酸化衍生物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756953A (fr) * 1969-10-02 1971-04-01 Merck & Co Inc Potentialisation d'antibiotiques
JPS5631156B2 (de) * 1973-09-25 1981-07-20
IT1170618B (it) * 1981-01-13 1987-06-03 Foscama Biomed Chim Farma Preparato farmacologico di frutto sio-1,6-difosfato ad azione terapeutica nei pazienti ustionati
US4703040A (en) * 1985-04-03 1987-10-27 Markov Angel K Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP)
ATE78166T1 (de) * 1985-10-22 1992-08-15 Silvetti Anthony N Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
US4889844A (en) * 1985-10-22 1989-12-26 Silvetti Sr Anthony N Fructose containing wound healing preparation
AU607690B2 (en) * 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
JPS62243675A (ja) * 1986-04-15 1987-10-24 Kao Corp ｐＨ緩衝法
ATE139699T1 (de) * 1988-08-19 1996-07-15 Univ Australian Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel
GB8917414D0 (en) * 1989-07-29 1989-09-13 Translift Material Handling Narrow aisle lift truck
WO1991004748A1 (en) * 1989-09-29 1991-04-18 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
SE8904354D0 (sv) * 1989-12-21 1989-12-21 Matti Siren A pharmaceutical composition
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
JPH0558868A (ja) * 1991-08-27 1993-03-09 Kao Corp 親水性紫外線吸収剤及びこれを含有する化粧料
AU3943793A (en) * 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
JPH09155319A (ja) * 1995-12-13 1997-06-17 Takeo Tsutsui 重金属含有焼却灰等、シュレッダーダストの無公害化処理方法および再利用材の製造方法

Also Published As

Publication number Publication date
DE69329559T2 (de) 2001-05-31
IL105079A0 (en) 1993-07-08
DE69329559D1 (de) 2000-11-16
EP0728006B1 (de) 2000-10-11
CA2130805A1 (en) 1993-09-30
ES2151903T3 (es) 2001-01-16
JP3930556B2 (ja) 2007-06-13
GB2265310B (en) 1996-09-25
US5520926A (en) 1996-05-28
PT728006E (pt) 2001-04-30
WO1993018777A1 (en) 1993-09-30
JPH07504909A (ja) 1995-06-01
DK0728006T3 (da) 2000-10-30
NO943451L (no) 1994-09-16
AU3759093A (en) 1993-10-21
AU667887B2 (en) 1996-04-18
NO306808B1 (no) 1999-12-27
EP0728006A1 (de) 1996-08-28
IL105079A (en) 1998-06-15
NZ249915A (en) 1996-08-27
GB2265310A (en) 1993-09-29
GB9205800D0 (en) 1992-04-29
SG49899A1 (en) 1998-06-15
ZA931869B (en) 1994-09-16
GB9305344D0 (en) 1993-05-05
NO943451D0 (no) 1994-09-16
CA2130805C (en) 2003-06-24
GR3035117T3 (en) 2001-03-30

Similar Documents

Publication Publication Date Title
ATE196847T1 (de) Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen
ATE164067T1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
DE69526937T2 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
ATE154758T1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE275964T1 (de) Verwendung von betalycan zur verminderung der narbenbildung
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE69124382T2 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification